Goldman Sachs Healthcare News

This is selected healthcare news for Goldman Sachs, which is filed under Capital Firms. There are 8.3K news items for this page. Goldman Sachs is occasionally combined with Wolfe Research, Cigna and Behavioral Health in news items. A press release filter page is also available for Goldman Sachs.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/25/2022 Jefferies Financial Group Research Analysts Reduce Earnings Estimates for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) - Watch List News
... on XRAY. TheStreet lowered DENTSPLY SIRONA from a ‚Auc‚Au rating to a ‚Aud‚Au rating in a research note on Monday, November 14th. The Goldman Sachs Group cut their price target on DENTSPLY SIRONA from $41.00 to $34.00 and set a ‚Auneutral‚Au rating on the stock in a ...
watchlistnews.com
11/25/2022 Brokerages Set Humana Inc. (NYSE:HUM) Price Target at $579.00
... that have updated their coverage on the stock in the last year is $579.00. A number of research firms have weighed in on HUM. The Goldman Sachs Group increased their price objective on Humana from $522.00 to $575.00 and gave the stock a ‚Auneutral‚Au rating in a research report ...
zolmax.com
11/25/2022 Alignment Healthcare (NASDAQ:ALHC) Stock Rating Lowered by Raymond James
Raymond James cut shares of Alignment Healthcare ( NASDAQ:ALHC ‚Ai Get Rating ) from an outperform rating to a market perform rating in a report published on Monday, Marketbeat reports. Other analysts also recently issued reports about the company. The Goldman Sachs Group increased their target price on Alignment Healthcare from ...
modernreaders.com
11/25/2022 Healthcare of Ontario Pension Plan Trust Fund Buys New Position in Clover Health Investments, Corp. (NASDAQ:CLOV)
... the first quarter. BlackRock Inc. now owns 5,681,089 shares of the company's stock worth $20,168,000 after purchasing an additional 329,673 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Clover Health Investments by 56.9% in the first quarter. Goldman Sachs Group Inc. now owns ...
baseballnewssource.com
11/25/2022 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $235.83 Average PT from Analysts - Watch List News
... on Alnylam Pharmaceuticals from $192.00 to $200.00 and gave the company a ‚Aumarket perform‚Au rating in a report on Friday, September 9th. Finally, The Goldman Sachs Group upped their target price on Alnylam Pharmaceuticals from $239.00 to $270.00 and gave the company a ‚Aubuy‚Au rating in a report ...
watchlistnews.com
11/25/2022 AstraZeneca PLC (LON:AZN) Receives £108.15 Consensus PT from Analysts
... price among analysts that have covered the stock in the last year is ¬£109.61 ($129.61). AZN has been the subject of several analyst reports. The Goldman Sachs Group set a GBX 6,950 ($82.18) target price on shares of AstraZeneca in a report on Thursday, November 10th. Barclays reaffirmed an ‚Auoverweight ...
American Banking News
11/25/2022 CVS Health (CVS) – Investment Analysts’ Recent Ratings Updates
... to $125.00. They now have an ‚Auoverweight‚Au rating on the stock. - 11/3/2022 ‚Ai CVS Health had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $128.00 to $113.00. They now have a ‚Aubuy‚Au rating on the stock. - 11/2/2022 ‚Ai CVS Health was downgraded by ...
etfdailynews.com
11/25/2022 Weekly Research Analysts’ Ratings Changes for Beauty Health (SKIN)
Several brokerages have updated their recommendations and price targets on shares of Beauty Health (NASDAQ: SKIN) in the last few weeks: - 11/23/2022 ‚Ai Beauty Health had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $19.00. They now have a ‚Aubuy‚Au rating on ...
etfdailynews.com
11/25/2022 First Trust Health Care AlphaDEX Fund (NYSEARCA:FXH) Stock Price Up 0.5%
... period. Jane Street Group LLC purchased a new stake in shares of First Trust Health Care AlphaDEX Fund in the third quarter worth about $13,573,000. Goldman Sachs Group Inc. lifted its position in shares of First Trust Health Care AlphaDEX Fund by 1,456.3% in the second quarter. Goldman Sachs Group ...
etfdailynews.com
11/25/2022 First Trust Health Care AlphaDEX Fund (NYSEARCA:FXH) Stock Price Up 0.5%
... the period. Jane Street Group LLC purchased a new stake in First Trust Health Care AlphaDEX Fund during the third quarter valued at approximately $13,573,000. Goldman Sachs Group Inc. raised its holdings in shares of First Trust Health Care AlphaDEX Fund by 1,456.3% in the second quarter. Goldman Sachs Group ...
defenseworld.net
11/25/2022 Pfizer (NYSE:PFE) PT Set at $55.00 by Credit Suisse Group
... shares of Pfizer from $55.00 to $54.00 and set an ‚Auoverweight‚Au rating for the company in a research note on Wednesday, November 2nd. The Goldman Sachs Group set a $47.00 price target on shares of Pfizer in a research note on Tuesday, November 8th. Barclays lifted their price target ...
American Banking News
11/25/2022 HealthEquity (NASDAQ:HQY) Downgraded by StockNews.com
StockNews.com cut shares of HealthEquity (NASDAQ:HQY ‚Ai Get Rating) from a hold rating to a sell rating in a report released on Tuesday. Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group upgraded HealthEquity from a sell rating to a neutral rating ...
Dakota Financial News
11/25/2022 Beauty Health (NASDAQ:SKIN) PT Lowered to $19.00
Beauty Health (NASDAQ:SKIN ‚Ai Get Rating) had its target price lowered by investment analysts at The Goldman Sachs Group from $22.00 to $19.00 in a research note issued on Wednesday, Marketbeat Ratings reports. The brokerage presently has a ‚Aubuy‚Au rating on the stock. The Goldman Sachs Group's ...
baseballnewssource.com
11/25/2022 Sotera Health (NYSE:SHC) Price Target Cut to $8.00
Sotera Health (NYSE:SHC ‚Ai Get Rating) had its price objective reduced by analysts at The Goldman Sachs Group from $9.00 to $8.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a ‚Auneutral‚Au rating on the stock. The Goldman Sachs Group's target price suggests ...
defenseworld.net
11/25/2022 Cigna (NYSE:CI) PT Raised to $347.00 at Morgan Stanley
... on shares of Cigna from $310.00 to $330.00 and gave the stock a ‚Aubuy‚Au rating in a research report on Monday, August 8th. The Goldman Sachs Group upped their price target on shares of Cigna from $273.00 to $311.00 and gave the stock a ‚Auneutral‚Au rating in a ...
zolmax.com
11/25/2022 CVS Health (NYSE:CVS) Price Target Cut to $119.00
... price would indicate a potential upside of 18.93% from the company's previous close. Other analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their price objective on CVS Health from $128.00 to $113.00 and set a ‚Aubuy‚Au rating for the company in a ...
zolmax.com
11/25/2022 Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $56.56
... updated their coverage on the stock in the last year is $56.47. A number of equities research analysts have weighed in on PFE shares. The Goldman Sachs Group set a $47.00 price objective on shares of Pfizer in a report on Tuesday, November 8th. Morgan Stanley increased their price target ...
baseballnewssource.com
11/25/2022 HealthEquity (NASDAQ:HQY) Downgraded by StockNews.com - Stock Observer
StockNews.com cut shares of HealthEquity ( NASDAQ:HQY ‚Ai Get Rating ) from a hold rating to a sell rating in a report released on Tuesday. Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group upgraded HealthEquity from a sell rating to a neutral rating ...
thestockobserver.com
11/25/2022 Citigroup Increases Best Buy (NYSE:BBY) Price Target to $72.00
... to a ‚Auhold‚Au rating and cut their price objective for the company from $106.00 to $71.00 in a report on Thursday, July 28th. The Goldman Sachs Group increased their price objective on Best Buy from $56.00 to $59.00 and gave the company a ‚Aubuy‚Au rating in a report ...
defenseworld.net
11/25/2022 Oak Street Health (NYSE:OSH) Downgraded to Market Perform at Raymond James
... November 14th. Canaccord Genuity Group cut their price objective on Oak Street Health from $32.00 to $27.00 in a report on Wednesday, November 9th. The Goldman Sachs Group downgraded Oak Street Health from a buy rating to a neutral rating and cut their price objective for the company from $32.00 ...
theenterpriseleader.com
11/24/2022 Analysts Set Expectations for DENTSPLY SIRONA Inc.'s Q2 2023 Earnings (NASDAQ:XRAY) - Ticker Report
... weighed in on XRAY. Evercore ISI lifted their price objective on shares of DENTSPLY SIRONA to $34.00 in a report on Thursday, November 17th. The Goldman Sachs Group dropped their price objective on shares of DENTSPLY SIRONA from $41.00 to $34.00 and set a ‚Auneutral‚Au rating for the company ...
Ticker Report
11/24/2022 Kronos Worldwide (NYSE:KRO) Lowered to Hold at StockNews.com
... Tuesday, September 27th. TheStreet cut Kronos Worldwide from a b- rating to a c rating in a research note on Thursday, September 29th. Finally, The Goldman Sachs Group initiated coverage on Kronos Worldwide in a research note on Thursday, October 13th. They issued a sell rating and a $9.00 price ...
com-unik.info
11/24/2022 Kronos Worldwide (NYSE:KRO) Lowered to Hold at StockNews.com
... price target on Kronos Worldwide from $18.00 to $12.00 and set a buy rating on the stock in a report on Monday, October 17th. The Goldman Sachs Group assumed coverage on Kronos Worldwide in a report on Thursday, October 13th. They set a sell rating and a $9.00 price target ...
thelincolnianonline.com
11/24/2022 Apollon Wealth Management LLC Has $333,000 Stake in Novartis AG (NYSE:NVS) - American Banking News
... Arrowstreet Capital Limited Partnership now owns 1,992,558 shares of the company's stock valued at $174,847,000 after buying an additional 1,010,806 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Novartis by 27.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,781,596 shares ...
American Banking News
11/24/2022 Accolade, Inc. (NASDAQ:ACCD) Given Consensus Rating of “Moderate Buy” by Analysts
... Accolade in a research report on Wednesday, September 7th. They issued a ‚Aubuy‚Au rating and a $15.00 target price on the stock. Finally, The Goldman Sachs Group raised their target price on Accolade from $14.50 to $16.00 and gave the company a ‚Aubuy‚Au rating in a research report ...
defenseworld.net